Department of Pathology, University of New Mexico School of Medicine, University of New Mexico, MSC08 4640, Albuquerque, NM, 87131, USA.
Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Head Neck Pathol. 2022 Dec;16(4):1019-1033. doi: 10.1007/s12105-022-01457-2. Epub 2022 May 4.
Sinonasal malignancies constitute 3% of head and neck cancers, with squamous cell carcinoma (SCC) the most common histology. Neuroendocrine carcinomas (NEC) are rare, with a subset showing neuroendocrine carcinoma and a non-neuroendocrine component. The pathogenesis of these combined tumors is largely unknown, and TP53 driver mutations may play a role. A database search for combined NEC was performed across two institutions (UNM and UCSF) spanning 15 years. Excluding NUT midline carcinoma, 3 cases met inclusion criteria. All were morphologically NEC + SCC and underwent a comprehensive immunohistochemical evaluation. Tumors demonstrated two components histologically: moderately to poorly differentiated SCC and high-grade NEC. Divergent differentiation was confirmed with lineage-specific markers. Only one patient received neoadjuvant chemotherapy prior to surgery, with a remarkable response (a marked decrease in the size of the primary lesion and resolution of liver metastases). Immunohistochemical staining for p53 was increased in 2 of 3 cases (both components), suggesting a role in the carcinogenesis of these tumors. Aberrant expression of beta-catenin was not identified. One case tested positive for p16, which can be seen in high grade NECs due to inactivation of Rb gene. Additionally, both cases with a small cell NEC component expressed PD-L1, suggesting that immunotherapy may be an effective treatment. Findings in this study support the role of p53 mutation in a subset of combined NEC + SCC of the sinonasal tract. Recognition of this rare entity is essential for optimal management of these aggressive neoplasms.
鼻窦恶性肿瘤占头颈部癌症的 3%,其中鳞状细胞癌(SCC)最为常见。神经内分泌癌(NEC)较为罕见,其中一部分表现为神经内分泌癌和非神经内分泌成分。这些混合肿瘤的发病机制在很大程度上尚不清楚,TP53 驱动突变可能起作用。在两个机构(UNM 和 UCSF)跨越 15 年的时间里,对合并的 NEC 进行了数据库搜索。排除 NUT 中线癌后,有 3 例符合纳入标准。所有病例均为形态学上的 NEC+SCC,并进行了全面的免疫组织化学评估。肿瘤在组织学上表现为两个成分:中到低分化 SCC 和高级别 NEC。通过谱系特异性标志物确认了不同的分化。只有 1 例患者在手术前接受了新辅助化疗,反应显著(原发灶大小明显缩小,肝转移灶消失)。3 例中有 2 例(两个成分)的 p53 免疫组化染色增加,提示这些肿瘤的发生与 p53 突变有关。未发现β-连环蛋白的异常表达。1 例 p16 阳性,由于 Rb 基因失活,高级别 NEC 中可见 p16 阳性。此外,有小细胞 NEC 成分的 2 例均表达 PD-L1,提示免疫治疗可能是一种有效的治疗方法。本研究的发现支持了 p53 突变在鼻窦道混合 NEC+SCC 中的作用。认识到这种罕见实体对于这些侵袭性肿瘤的最佳管理至关重要。